In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
713: Making Chemistry More Accessible To Blind And Low-Vision People
712: Understanding And Curbing Generative AI’s Energy Consumption
711: Which Feathered Dinosaurs Could Fly? | Some French Cheeses At Risk Of Extinction
710: Climate Scientist Michael Mann Wins Defamation Case
709: Odysseus Lander Heads To The Moon | Ohio Chemical Spill, One Year Later
708: One Crisis After Another: Designing Cities For Resiliency
707: Using Sound To Unpack The History Of Astronomy
706: Colorectal Cancer Rates Rising In Young People | What An AI Learns From A Baby
705: A Black Physician’s Analysis Of The Legacy Of Racism In Medicine
704: Faraway Planets With Oceans Of Magma | The Art And Science Of Trash Talk
701: Is Each Fingerprint On Your Hand Unique? | In This Computer Component, Data Slides Through Honey
700: The FDA Approved The First CRISPR-Based Therapy. What’s Next?
703: Protecting The ‘Satan’ Tarantula | If Termites Wore Stripes, Would Spiders Still Eat Them?
699: Scientists Are Uncovering A World Of ‘Dark Matter’ Carcinogens
702: Syphilis Cases Up 80% Since 2018 | The Largest Deep-Sea Coral Reef In The World
698: Expanding Our Umwelt: Understanding Animal Experiences
695: How Signing Characters Help Deaf Children Learn Language
696: ‘Mysterious’ Canine Illness: What Dog Owners Should Know
694: An App For People Of Color To Rate Their Birthing Experiences | How Different Animals See
697: NASA Opens Canister With Asteroid Sample | ADHD Prescription Rates Spiked During The Pandemic
Create your
podcast in
minutes
It is Free
The Modern West
Voices of Misery Podcast
House of Whimsical Terror
Dairyland Frights
Stuff You Should Know
Timcast IRL